Table 1.
Demographic characteristics and laboratory data at baselines among CAD patients stratified by medians of matrix metalloproteinase-2, -3 and -9 levels, respectively.
Figure 1.
Whisker plots showing the 10th, 25th, 50th, 75th and 90th percentiles distribution of eGFR slope.
Difference between patients with MMP-2 (A), MMP-3 (B) and MMP-9 (C) above and below the medians, respectively. Medians of baseline plasma MMP-2, MMP-3 and MMP-9 levels were 861 ng/mL, 227 ng/mL, and 49 ng/mL, respectively. Abbreviations: eGFR, estimated glomerular filtration rate; MMP, matrix metalloproteinase.
Table 2.
Comparison of baseline parameters between patients who did and did not reach the endpoint defined by an eGFR decline more than 25% from baseline.
Figure 2.
Kaplan-Meier analysis of survival curves in CAD patients.
Progression-free (A) and mortality-free (B) survivals are the study endpoints. Difference between patients with MMP-2, MMP-3 and MMP-9 above and below the medians, respectively, by log-rank test. Medians of baseline plasma MMP-2, MMP-3 and MMP-9 levels were 861 ng/mL, 227 ng/mL, and 49 ng/mL, respectively. Abbreviations: CAD, coronary artery disease; MMP, matrix metalloproteinase.
Table 3.
Univariate analysis for the predictors of kidney disease progression and mortality in patients with coronary artery disease.
Table 4.
Multivariate Cox proportional hazard regression models for the prediction of kidney disease progression and mortality among patients with coronary artery disease.
Figure 3.
MMP risk score in renal and mortality outcomes in patients with stable CAD.
Outcomes contain eGFR decline rate (A), incidence of renal progression (B), and overall mortality rate (C). Abbreviations: CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; MMP, matrix metalloproteinase.
Table 5.
Discriminative ability of conventional risk factors and addition of MMPs for prediction of chronic kidney disease progression.